Should NSCLC Patients Receive Immunotherapy 'Indefinitely'?
Most long-term responders to immunotherapy continue taking the drugs after 2 years. But data show long-term use likely offers no survival benefit.
Medscape Medical News
source https://www.medscape.com/viewarticle/996496?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/996496?src=rss
Comments
Post a Comment